A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was 'In patients with carcinoid syndrome undergoing valve replacement, will a biological valve have acceptable durability?' Altogether, more than 130 papers were found using the reported search, of which 17 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. The pooled data from all papers represent 51 patients with carcinoid right heart disease who underwent tricuspid valve replacement. Two 'outcomes' studies reported a 30-day postoperative mortality of 16.7-18% and 2-year survival rates of 44 and 50%, respectively. Seventeen patients were detailed in case reports. Of these 17 patients, 7 died during the follow-up period. All but one of these patients had a normal bioprosthesis at echocardiography or at post-mortem. One patient with a plaque-covered valve had a functionally normal valve. We conclude that at present, the best available evidence suggests that although 30-day mortality approaches 20%, approximately half of patients with carcinoid syndrome undergoing tricuspid valve replacement can be expected to survive 2 years. Some patients survive considerably longer than this, beyond 10 years in some cases. Importantly, at autopsy, many replacement valves have been shown to be normal, with a few patients reported as having died of cardiac causes. This should be taken as cautious evidence that biological valves have an acceptable lifespan in patients with carcinoid syndrome and that the process of valve destruction seen in carcinoid patients does not continue to a significant level in the bioprosthesis. Caveats to this include the lack of any directly comparative trial and the predominance of case reports as opposed to higher-level evidence.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
A 55-year old man presents with severe tricuspid valve regurgitation. He is known to have metastatic carcinoid syndrome, with evidence of disease in the liver. However, the oncologists tell you that he potentially has several years of good-quality life ahead of him as it is a slow-growing tumour. You tell him that you will be putting biological valves in him, but he asks whether his carcinoid syndrome will destroy the new valve just as it did his native valves. You had not thought about this so you resolve to check the literature. 
SEARCH STRATEGY
SEARCH OUTCOME
One hundred and thirty papers were found using the reported search. From these, 17 papers were identified that provided the best evidence to answer the question. These are presented in Table 1 . prostheses. The generalisability of the evidence found is limited by low power and varying treatment protocols in different centres. The pooled data from all papers represent 51 patients with carcinoid right heart disease who underwent tricuspid valve replacement. The papers are also limited by variable lengths of the followup periods. Of the papers that reported the length of the followup period, the mean length was 34.1 months (range 3-153 months). The longest survival reported after tricuspid replacement was 153 months [2] . Two outcome studies reported a 30-day postoperative mortality of 16.7-18% [3, 4] . The 2-year survival rates from these studies were 44 and 50%, respectively. Important to note, is that one series reported the longest survival and follow-up periods of 146 and 153 months [2] . Excluding these, the average length of the follow-up, regardless of the patient's status at the end of the follow-up, was 21 months.
Of the 51 patients, 34 were reported in the two-level three-outcome analyses in which the individual status of each patient was not detailed [3, 4] . The remaining 17 patients were detailed in case reports. Of these 17 patients, 7 died during the follow-up period. Of the three patients alive at the end of the Robiolio et al.'s [2] follow-up period, two died of noncardiac causes and one of these, who died after 153 months, had undergone cardiac catheterization at 107 months, demonstrating a normal replacement of tricuspid valve but a failing native pulmonary valve. Ohri et al. [5] reported that the case of a 64-year old woman who underwent tricuspid replacement with a Carpentier-Edwards bioprosthesis but died after 3 months due to pulmonary regurgitation and hypertension. Autopsy showed that the replacement of bioprosthesis was normal. In Lundin et al.'s [6] series, one patient died 5 days postoperatively of septicaemia. DiSesa et al. [7] reported that the case of a patient who died after 49 months. Post-mortem examination revealed that the replacement of bioprosthesis was not thickened and was functioning normally. 
CLINICAL BOTTOM LINE
At present, the best available evidence suggests that although 30-day mortality approaches 20%, approximately half of patients with carcinoid syndrome undergoing tricuspid valve replacement can be expected to survive 2 years. Some patients survive considerably longer than this, beyond 10 years in some cases. Importantly, at autopsy many replacement valves have been shown to be normal, with few patients being reported to die of cardiac causes. This should be taken as cautious evidence that biological valves have an acceptable lifespan in patients with carcinoid syndrome and that the process of valve destruction seen in carcinoid patients does not continue to a significant level in the bioprosthesis. Caveats to this include the lack of any directly comparative trial and the predominance of case reports as opposed to higher-level evidence.
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